GlobeImmune sets IPO price range in $75m fundraising effort
This article was originally published in Scrip
Executive Summary
With its cash balance waning, GlobeImmune has set early pricing parameters for its initial public offering at $11 to $13 per share for five million shares of common stock, which will gross $55-65 million for the Louisville, Colorado-based company's mid-stage oncology drug candidate optioned by Celgene and early-stage hepatitis B virus (HBV) asset licensed to Gilead Sciences.